• News
  • Media
  • Conferences
  • Publications
  • Events
  • CE
  • Resources
  • Subscribe

E. Bridget Kim, PharmD, BCPS, BCOP

Articles by E. Bridget Kim, PharmD, BCPS, BCOP

B-cell lymphoma -- Image credit: Arif Biswas | stock.adobe.com

Bispecific T-Cell–Engaging Antibodies in B-Cell Lymphoma: Efficacy, Safety, and Practical Considerations

ByUvette Lou, PharmD, BCOP,Brenna Rowan, PharmD, BCOP,Abigail McLaren, PharmD, MS,E. Bridget Kim, PharmD, BCPS, BCOP,Mark N. Sorial, PharmD, BCOP,J. Erika Haydu, MD, PhD,Matthew M. Lei, PharmD, BCOP

This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.

Blood sample positive for multiple myeloma -- Image credit: angellodeco | stock.adobe.com

Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma

ByMatthew M. Lei, PharmD, BCOP,Jack Malespini, PharmD, BCOP,Erica Tavares, PharmD, BCPS, BCOP,Sarah O'Neill, PharmD,Diana Cirstea, MD,E. Bridget Kim, PharmD, BCPS, BCOP

Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.

Latest Updated Articles